## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 6.2% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. MRS_5 (6.2%) even more extended - blow-off risk elevated.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($1002.77)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history**
- Source: Fierce Pharma | 20251213T150828 | Neutral | Relevance: 100%
- Eli Lilly will not seek a broad FDA approval for its oral SERD Inluriyo combined with Verzenio for breast cancer, instead focusing on a more limited label for patients with ESR1 gene mutations. Despite promising results for the combination in a wider patient group, the company acknowledges difficulties with FDA approval for an all-comers indication. Lilly is now directing its efforts towards the adjuvant setting with the Ember-4 trial, which will be its largest oncology trial, to test Inluriyo in a post-CDK4/6 environment.

**2. Scotiabank remains bullish on Eli Lilly and Company (LLY)**
- Source: MSN | 20251216T040803 | Bullish | Relevance: 100%
- Scotiabank reiterates its Outperform rating on Eli Lilly and Company (LLY). The firm emphasizes that despite the current valuation, significant potential remains due to the anticipated launch of multiple new products across large therapeutic areas, particularly with the expanding market of obesity drugs like Zepbound.

**3. American Trust Buys 3,644 Shares of Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251215T080815 | Bullish | Relevance: 100%
- American Trust significantly increased its stake in Eli Lilly and Company (NYSE:LLY) by 147.1% during the second quarter, bringing its total holdings to 6,122 shares valued at approximately $4.77 million. This move comes as Eli Lilly reported strong earnings, exceeding analyst expectations, and provided optimistic future guidance. Other institutional investors have also shown increased interest, with a substantial 82.53% of the company's stock now owned by institutional investors.

**4. Eli Lilly Stock Price Today | NYSE: LLY Live**
- Source: Investing.com | 20251213T110840 | Bullish | Relevance: 100%
- This article provides a live overview of Eli Lilly and Company (LLY) stock performance, including its current price, market data, and a summary of recent news and analyst ratings. It highlights the company's strong position in diabetes and obesity treatments, robust financial outlook, and pipeline potential, while also offering key financial metrics and a technical analysis summary.

**5. Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)**
- Source: ts2.tech | 20251213T020901 | Bullish | Relevance: 100%
- Eli Lilly (LLY) stock saw a 3% gain last week driven by positive news regarding its pipeline, including promising Phase 3 results for retatrutide in obesity, an EMA committee recommendation to expand Mounjaro for pediatric type 2 diabetes, and discussions about accelerating orforglipron's FDA review. The company also announced a significant $6 billion investment in a new manufacturing facility and a dividend hike. Investors are currently weighing the growth potential of these developments against competition, pricing pressures, and manufacturing execution risks.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($2.06M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $208M sold (30 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +12.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 32.7x attractive for 37% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (6 raises, avg +12%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $952.2B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 32.7 |
| Current P/E | 44.9 |
| YoY Growth | 37.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -6.6% to 6.2% (+12.8% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (6.2% > 6.0%), caution on chasing. MRS_5 at 6.2% confirms short-term momentum alignment. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-8.64), momentum weakening. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 6.16% (CS: 93) | Strong |
| RSI_14 | 64.2 | Neutral |
| MACD Histogram | -8.64 | Bearish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.131x | Above |
| vs SMA200 | 1.303x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $1062.19
- **Stop Loss:** $1002.77 (5.6% risk)
- **Target:** $1121.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $21,243.80
- **Portfolio %:** 21.24%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*